Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach

Anti-Cancer Drugs

Volumn 23, Issue 5, 2012, Pages 483-493

  Al Safadi, Sherin ^a   Domarkas, Juozas ^b   Han, Yingshan ^a   Brahimi, Fouad ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

apoptosis; combi molecule; DNA damage; epidermal growth factor receptor; quinazoline; triazene; tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; FD 105; JDE 52; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ZRBA 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL KILLING; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DNA DAMAGE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MALE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; SOLID TUMOR;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; COMET ASSAY; DNA BREAKS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FLOW CYTOMETRY; HUMANS; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZENES;

EID: 84863410726     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328351c101     Document Type: Article

References (37)

1. Lin S, Makino K, XiaW, Matin A,Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3:802-808. (Pubitemid 32842685)
2. Lo H, Hsu S, Hung M. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 2005; 95:211-218.
3. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366:2-16. (Pubitemid 43199589)
4. Pal S, Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 2005; 16: 483-494. (Pubitemid 40685732)
5. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007; 19:2013-2023. (Pubitemid 47353811)
6. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319:1-11.
7. Burgess A, Cho H, Eigenbrot C, Ferguson K, Garrett T, Leahy D, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541-552. (Pubitemid 37222478)
8. Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ. The combitargeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes". J Med Chem 2003; 46:4313-4321. (Pubitemid 37153012)
9. Qiu Q, Domarkas J, Banerjee R, Merayo N, Brahimi F, McNamee J, et al. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combinitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res 2007; 13:331-340. (Pubitemid 46121887)
10. Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee J, Jean-Claude BJ. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05. Anticancer Drugs 2007; 18:171-177. (Pubitemid 44967427)
11. Sabharwal A, Middleton M. Exploiting the role of O6-methylguanine- DNAmethyltransferase (MGMT) in cancer therapy. Curr Opin Pharmacol 2006; 6:355-363.
12. Banerjee R, Rachid Z, McNamee J, Jean-Claude BJ. Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J Med Chem 2003; 46:5546-5551. (Pubitemid 37490384)
13. Brahimi F, Matheson S, Dudoit F, McNamee J, Tari A, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-Triazene" BJ2000, a new probe for combi-targeting postulates. J Pharm Exp Ther 2002; 303:832-840.
14. Brahimi F, Rachid Z, McNamee J, Alaoui-Jamali M, Tari A, Jean-Claude BJ. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol 2005; 70:511-519. (Pubitemid 40978540)
15. Matheson S, McNamee J,Wang T, Alaoui-Jamali M, Tari A, Jean-Claude BJ. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharmacol Exp Ther 2004; 311:1163-1170. (Pubitemid 39612724)
16. Matheson S, Brahimi F, Jean-Claude BJ. The combi-targeting concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41. Biochem Pharmacol 2004; 67:1131-1138. (Pubitemid 38296792)
17. Matheson S, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl- 1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther 2001; 296:832-840. (Pubitemid 32187355)
18. Matheson S, McNamee J, Jean-Claude BJ. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother Pharmacol 2003; 51:11-20. (Pubitemid 36057018)
19. Middleton M, Margison G. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 2003; 4:37-44. (Pubitemid 36124189)
20. Heravi M, Rachid Z, Goudarzi A, Schlisser A, Jean-Claude BJ. Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Anticancer Drugs 2009; 20:659-667.
21. Herr I, Debatin K. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98:2603-2614.
22. Heymach J, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of nonsmall cell lung cancer. Clin Cancer Res 2006; 12:4441s-4445s. (Pubitemid 44197196)
23. Bogoyevitch M, Barr R, Ketterman A. Peptide inhibitors of protein kinases-discovery, characterization and use. Biochim Biophys Acta 2005; 1754: 79-99.
24. Ying W, Sanders P. EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells. J Am Soc Nephrol 2007; 18:131-142. (Pubitemid 46053428)
25. Zhang T, Xinmin C. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. Biochemical Society 2003; 376:457-464. (Pubitemid 38010531)
26. Yen L, Benlimame N, Nie ZR, Ziao D, Wang T, Al Moustafa AE, et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 2002; 13:4029-4044. (Pubitemid 35398568)
27. Banerjee R, Huang Y, McNamee J, Todorova M, Jean-Claude BJ. The combi-targeting concept: selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24. J Pharmacol Exp Ther 2010; 334:9-20.
28. MacPhee M, Rachid Z, Todorova M, Jean-Claude BJ. Characterization of the potency of the epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Invest New Drugs 2011; 20:833-845.
29. Tchou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
30. Olive P, Banath J. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 2006; 1:23-29.
31. Joytchev G, Menke M, Schubert I. The comet assay detects adaptation to MNU-induced damage in barley. Mutat Res 2001; 493:95-100. (Pubitemid 32539433)
32. Ueda-Kawamitsu H, Lawson T, Gwilt P. In vitro pharmacokinetics and pharmacodynamics of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 2002; 63:1209-1218. (Pubitemid 34311990)
33. Domarkas J, Qiyu Q, Brahimi F, Banerjee R, Jean-Claude BJ. The combitargeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 2006; 49:3544-3552. (Pubitemid 43902460)
34. Merayo N, Rachid Z, Qiu Q, Brahimi F, Jean-Claude BJ. The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anticancer Drugs 2006; 17:165-171.
35. Zwick E, Ullrich A. Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 2001; 8:161-173. (Pubitemid 32947638)
36. Wong R, Guillaud L. The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev 2004; 15:147-156. (Pubitemid 38521250)
37. Hatake K, Tokudome N, Ito Y. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways. Breast Cancer Res Treat 2007; 14:132-149.